[ad_1]
CAMBRIDGE, Mbadachusetts – (Business Wire) – Vedanta
Biosciences a subsidiary of PureTech
Health (LSE: PRTC) developing a new category of therapies
Immune-mediated and infectious diseases based on a rational definition
consortia of human bacteria derived from the microbiome, announced today
received funding from the Crohn & Colitis Foundation, a non-profit organization
organization dedicated to finding remedies for Crohn's disease and
ulcerative colitis. The funds will be used to advance Vedanta
New therapeutic program derived from the microbiome of Biosciences for
Potential treatment and interception of inflammatory bowel disease
(IBD). This program is advanced in collaboration with Dr. Kenya
Honda, M.D., Ph.D., Professor, Keio University School of Medicine and a
Scientific co-founder of Vedanta Biosciences.
"As the first commercial organization to benefit from financing
auspices of the newly launched entrepreneurial investment by the Foundation
Initiative, we are excited about the potential of Vedanta's research to
bringing microbiome-derived therapies to our patients, "said Michael Osso,
President and CEO of the Crohn & Colitis Foundation. "Foundation-led
the research helped determine that the gut microbiome is a key link
between genetic susceptibility and the onset and progression of IBD.
The pioneering work of Vedanta promised to advance the discoveries in this
domain to new therapeutic options for IBD patients. "
This new program of IBD wholly owned by Vedanta Biosciences, aims
to target pathogenic bacterial strains, particularly abundant in Crohn's
the disease, which can lead to the emergence of IBD. IBD is supposed to train
interactions between genetic factors and environmental triggers,
such as commensal bacteria with pathogenic potential (pathobionts). In
fundamental work recently published in Science ,
Dr. The Honda group has shown in preclinical studies that
colonization with pathobiont Klebsiella pneumoniae active
pro-inflammatory helper 1 T cells in the intestine, resulting in intestinal
inflammation and leading to the onset of IBD. In the current preclinical work,
Vedanta Biosciences has identified consortia of beneficial intestinal bacteria
which can potentially target and decolonize Klebsiella .
"Dr. Honda's Research Suggests an All-New Approach to Help IBD
patients by the specific elimination of pro-inflammatory bacteria. we
believe that this approach could be exploited both to treat IBD
as well as intercept the progression of the disease in its early stages
or before the diagnosis, "said Bernat Olle, Ph.D., co-founder and chief
Executive Director of Vedanta Biosciences. "We are grateful to
Crohn's and Colitis Foundation for their support and for the occasion
work closely with patient groups to find a cure for IBD. "
In addition to this program, Vedanta Biosciences has previously announced
partnership with Janssen Biotech, Inc. for drug development
VE202 candidate in IBD. VE202 is based on a rational definition
consortium of bacteria with immunoregulatory properties. VE202 is
should enter the clinic in the second half of 2018.
About Inflammatory Bowel Disease
Inflammatory Bowel Disease
(IBD) is estimated to affect 1.6 million people in the United States,
with up to 70,000 new cases of the disease diagnosed each year. the
The exact cause of ITN is not fully understood, but it is badociated with
chronic inflammation of the gastrointestinal tract (GI), which
the ability of affected GI organs to function properly. Symptoms may vary
but include diarrhea, abdominal pain, cramps, rectal bleeding and
tired. Currently available medications relieve inflammation and
reduce symptoms but do not cure or prevent long-term
complications.
About the Crohn's and Colitis Foundation
The Crohn's & # 39; s &
Colitis Foundation is the largest non-profit, voluntary, health
organization dedicated to finding remedies for inflammatory bowel disease
(IBD). The mission of the Foundation is to cure Crohn's disease and
ulcerative colitis, and to improve the quality of life of children and
adults who are affected by these diseases. The Foundation works to
fulfill its mission by funding research; provide educational resources
for patients and their families, health professionals and the public;
and provide support services to people with IBD. For
more information visit http://www.crohnscolitisfoundation.org/
call 888-694-8872 or send an email to [email protected].
About Vedanta Biosciences
Vedanta
Biosciences is a clinical phase company developing a new category of
therapies for immune and infectious diseases based on
rationally defined consortia of human bacteria derived from the microbiome. A
affiliated with PureTech
Health (PureTech Health plc, PRTC.L), Vedanta Biosciences is a
leader in the field of microbiome with advanced capabilities and expertise for
discover, develop and manufacture drugs containing living bacteria. These included
what is considered the largest collection of man
bacterial strains badociated with the microbiome, a series of proprietary tests
select pharmacologically powerful strains, large proprietary datasets
Human intervention studies and GMP-compliant facilities
production of rationally defined bacterial consortia in the form of powder.
The pioneering work of Vedanta Biosciences, in collaboration with
scientific co-founders, led to the identification of human commensals
bacteria that induce a range of immune responses – including induction
regulatory T cells, CD8 + T cells and Th17 cells, among others. These
Progress has been published in peer-reviewed journals including Science (multiple) Nature ( multiple ) ] [19659014] Cell and Nature
Immunology . Vedanta Biosciences exploited these
biological knowledge and its ability to generate a pipeline of
programs in infectious diseases, autoimmune diseases, allergies and
immuno-oncology.
The scientific co-founders of Vedanta Biosciences are world-renowned experts
in immunology and microbiology who were the first to innovate
immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan
Medzhitov (Yale Medical Institute and Howard Hughes (HHMI)), Dr. Brett
Finlay (University of British Columbia and HHMI), Dr. Kenya Honda
(inventor of the main product candidate of Vedanta Biosciences, Keio
University and RIKEN), Dr. Dan Littman (New York University and HHMI),
Dr. Alexander Rudensky (Sloan Kettering and HHMI) and Dr. Jeremiah
Faith (Mount Sinai School of Medicine).
Forward-looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements regarding PureTech's future prospects, developments and
strategies. Forward-looking statements are based on
expectations and are subject to known and unknown risks and
uncertainties that could lead to results, performance and
achievements differ significantly from current expectations, including:
but without limiting it, the risks and uncertainties described in the risk
the factors included in the regulatory documents of PureTech Health. These
Forward-looking statements are based on badumptions about
current and future business strategies of the company and
environment in which it will operate in the future. Every avant-garde
statement speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither PureTech Health nor
any other party intends to update or revise these
statements, whether as a result of new information, future events or
other.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20180709005739/en/
Investors
PureTech Health plc
Allison Mead, + 1
617-651-3156
[email protected]
or
U.S.
Media
Ten Bridge Communications
Tom Donovan, +1
857-559-3397
[email protected]
[ad_2]
Source link
